Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05005728
Title XmAb20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors Xencor, Inc.
Indications

castration-resistant prostate carcinoma

Therapies

XmAb20717

Olaparib + XmAb20717

Cabazitaxel + Carboplatin + XmAb20717

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Recruiting Duarte California 91010 United States Details
University of Iowa Hospitals & Clinics Recruiting Iowa City Iowa 52242 United States Details
GU Research Network/Urology Cancer Center Recruiting Omaha Nebraska 68130 United States Details
Comprehensive Cancer Centers of Nevada Recruiting Las Vegas Nevada 89148 United States Details
XCancer New Mexico Oncology Hematology Consultants, Ltd. Recruiting Albuquerque New Mexico 87109 United States Details
Montefiore Medical Center Recruiting Bronx New York 10461 United States Details
Columbia University Recruiting New York New York 10032 United States Details
University of Pannsylvania Recruiting Philadelphia Pennsylvania 19104 United States Details
UPMC Hillman Cancer Center Recruiting Pittsburgh Pennsylvania 15232 United States Details
University of Washington/Seattle Cancer Care/Alliance Recruiting Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field